Wynzora

Wynzora combines betamethasone and calcipotriol for topical treatment of psoriasis. This corticosteroid and vitamin D analog reduces inflammation and skin cell overgrowth. Suitable for adults, it provides localized relief for mild to moderate plaque psoriasis. A trusted option for managing psoriasis symptoms effectively.

Wynzora is used to treat mild to moderate plaque psoriasis in adults. It helps reduce redness, scaling, and itching associated with psoriatic skin plaques. The combination of betamethasone and calcipotriol works to slow skin cell growth and decrease inflammation. It is applied directly to affected skin areas as directed by a healthcare provider.

Wynzora provides relief from psoriasis symptoms such as redness, scaling, and itching. Users may notice reduced plaque thickness and improved skin appearance over time. The medication works locally on the skin without systemic effects when used as prescribed. Some individuals experience mild skin irritation or dryness at the application site.

Wynzora is for external use only and should not be applied to the face, groin, or underarms unless directed. Avoid contact with eyes, mouth, or broken skin. Wash hands before and after application to prevent unintended spread. Do not use occlusive dressings unless advised by a healthcare professional. Keep out of reach of children.

Avoid using Wynzora with other topical corticosteroids or vitamin D analogs to prevent excessive exposure. Inform your healthcare provider about all medications, including over-the-counter products and supplements. Alcohol-based products or harsh soaps may increase skin irritation when used with Wynzora. No significant systemic drug interactions are reported for topical use.